PF-Atlas › Clinical Trials › NCT00442611
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis
Abatacept · Phase 1
Registry ID
NCT00442611
Phase
Phase 1
Status
Completed
Drug / intervention
Abatacept
Sponsor
Stanford University
Start
2008-11
Enrollment
10
Locations
1
About this trial
Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease that involves the skin and other internal organs for which there are few effective treatment options. We hypothesize that treatment with abatacept, a new therapy recently approved for the treatment of rheumatoid arthritis, may reduce the progression of skin thickening and fibrosis in people with scleroderma.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00442611 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.